Cargando…

Modulation of the Immune Response by Deferasirox in Myelodysplastic Syndrome Patients

Deferasirox (DFX) is an oral iron chelator used to reduce iron overload (IO) caused by frequent blood cell transfusions in anemic myelodysplastic syndrome (MDS) patients. To study the molecular mechanisms by which DFX improves outcome in MDS, we analyzed the global gene expression in untreated MDS p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Votavova, Hana, Urbanova, Zuzana, Kundrat, David, Dostalova Merkerova, Michaela, Vostry, Martin, Hruba, Monika, Cermak, Jaroslav, Belickova, Monika
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7825690/ https://www.ncbi.nlm.nih.gov/pubmed/33430232 http://dx.doi.org/10.3390/ph14010041

Ejemplares similares

Differential Expression of MicroRNAs in CD34+ Cells of 5q- Syndrome
por: Votavova, Hana, et al.
Publicado: (2011)

TP53 mutation variant allele frequency is a potential predictor for clinical outcome of patients with lower-risk myelodysplastic syndromes
por: Belickova, Monika, et al.
Publicado: (2016)

LncRNA Profiling Reveals That the Deregulation of H19, WT1-AS, TCL6, and LEF1-AS1 Is Associated with Higher-Risk Myelodysplastic Syndrome
por: Szikszai, Katarina, et al.
Publicado: (2020)

Circulating Small Noncoding RNAs Have Specific Expression Patterns in Plasma and Extracellular Vesicles in Myelodysplastic Syndromes and Are Predictive of Patient Outcome
por: Hrustincova, Andrea, et al.
Publicado: (2020)

Hypoplastic myelodysplastic syndrome and acquired aplastic anemia: Immune-mediated bone marrow failure syndromes (Review)
por: Votavova, Hana, et al.
Publicado: (2021)

Relationship between Altered miRNA Expression and DNA Methylation of the DLK1-DIO3 Region in Azacitidine-Treated Patients with Myelodysplastic Syndromes and Acute Myeloid Leukemia with Myelodysplasia-Related Changes
por: Merkerova, Michaela Dostalova, et al.
Publicado: (2018)

DNA repair gene variants are associated with an increased risk of myelodysplastic syndromes in a Czech population
por: Belickova, Monika, et al.
Publicado: (2013)

Circular RNAs in Hematopoiesis with a Focus on Acute Myeloid Leukemia and Myelodysplastic Syndrome
por: Dostalova Merkerova, Michaela, et al.
Publicado: (2020)

RUNX1 mutations contribute to the progression of MDS due to disruption of antitumor cellular defense: a study on patients with lower-risk MDS
por: Kaisrlikova, Monika, et al.
Publicado: (2022)

Low Plasma Citrate Levels and Specific Transcriptional Signatures Associated with Quiescence of CD34(+) Progenitors Predict Azacitidine Therapy Failure in MDS/AML Patients
por: Koralkova, Pavla, et al.
Publicado: (2021)

Deferasirox-induced urticarial vasculitis in a patient with myelodysplastic syndrome
por: Polat, Asude Kara, et al.
Publicado: (2017)

Protein Carbonylation in Patients with Myelodysplastic Syndrome: An Opportunity for Deferasirox Therapy
por: Rodríguez-García, Alba, et al.
Publicado: (2019)

Plasma protein alterations in the refractory anemia with excess blasts subtype 1 subgroup of myelodysplastic syndrome
por: Májek, Pavel, et al.
Publicado: (2012)

Plasma Protein Biomarker Candidates for Myelodysplastic Syndrome Subgroups
por: Majek, Pavel, et al.
Publicado: (2015)

Molecular Fingerprints of Borderline Changes in Kidney Allografts Are Influenced by Donor Category
por: Hruba, Petra, et al.
Publicado: (2020)

Proteome Changes in the Plasma of Myelodysplastic Syndrome Patients with Refractory Anemia with Excess Blasts Subtype 2
por: Majek, Pavel, et al.
Publicado: (2014)

circGPA: circRNA functional annotation based on probability-generating functions
por: Ryšavý, Petr, et al.
Publicado: (2022)

Plasma proteome changes associated with refractory anemia and refractory anemia with ringed sideroblasts in patients with myelodysplastic syndrome
por: Májek, Pavel, et al.
Publicado: (2013)

Peripheral Blood Mononuclear Cell Proteome Changes in Patients with Myelodysplastic Syndrome
por: Pecankova, Klara, et al.
Publicado: (2015)

CBFB-MYH11 hypomethylation signature and PBX3 differential methylation revealed by targeted bisulfite sequencing in patients with acute myeloid leukemia
por: Hájková, Hana, et al.
Publicado: (2014)

Transfusion-dependent low-risk myelodysplastic patients receiving deferasirox: Long-term follow-up
por: IMPROTA, SALVATORE, et al.
Publicado: (2013)

Proteome changes of plasma-derived extracellular vesicles in patients with myelodysplastic syndrome
por: Pecankova, Klara, et al.
Publicado: (2022)

Enhanced levels of asymmetric dimethylarginine in a serum of middle age patients with myelodysplastic syndrome
por: Štikarová, Jana, et al.
Publicado: (2013)

Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study
por: Porter, John, et al.
Publicado: (2008)

Posttranslational Modifications of Red Blood Cell Ghost Proteins as “Signatures” for Distinguishing between Low- and High-Risk Myelodysplastic Syndrome Patients
por: Pecankova, Klara, et al.
Publicado: (2017)

Deferasirox – a rarer cause of Fanconi syndrome
por: Khan, Iman, et al.
Publicado: (2019)

Reactive oxygen species levels control NF-κB activation by low dose deferasirox in erythroid progenitors of low risk myelodysplastic syndromes
por: Meunier, Mathieu, et al.
Publicado: (2017)

Hypersensitivity reaction with deferasirox
por: Sharma, Atul, et al.
Publicado: (2015)

Clonal evolution in myelodysplastic syndromes
por: da Silva-Coelho, Pedro, et al.
Publicado: (2017)

S169: MODULATION OF THE IMMUNE LANDSCAPE IN LOWER-RISK MYELODYSPLASTIC SYNDROMES WITH IMETELSTAT-INDUCED TRANSFUSION INDEPENDENCY
por: Chapuis, Nicolas, et al.
Publicado: (2023)

Plasma Levels of Aminothiols, Nitrite, Nitrate, and Malondialdehyde in Myelodysplastic Syndromes in the Context of Clinical Outcomes and as a Consequence of Iron Overload
por: Pimková, Kristýna, et al.
Publicado: (2014)

Deferasirox treatment of iron-overloaded chelation-naïve and prechelated patients with myelodysplastic syndromes in medical practice: results from the observational studies eXtend and eXjange
por: Gattermann, Norbert, et al.
Publicado: (2012)

A New Approach for the Diagnosis of Myelodysplastic Syndrome Subtypes Based on Protein Interaction Analysis
por: Chrastinová, Leona, et al.
Publicado: (2019)

Health-Related Quality of Life, Treatment Satisfaction, Adherence and Persistence in β-Thalassemia and Myelodysplastic Syndrome Patients with Iron Overload Receiving Deferasirox: Results from the EPIC Clinical Trial
por: Porter, John, et al.
Publicado: (2012)

Immune dysregulation in myelodysplastic syndrome
por: Sugimori, Chiharu, et al.
Publicado: (2010)

Immune Mechanisms in Myelodysplastic Syndrome
por: Glenthøj, Andreas, et al.
Publicado: (2016)

Reversal of T-cell Tolerance in Myelodysplastic Syndrome through Lenalidomide Immune Modulation
por: McDaniel, Jessica M., et al.
Publicado: (2011)

Deferasirox: Duodenal perforation: case report
Publicado: (2021)

Synthesis and Study of Multifunctional Cyclodextrin–Deferasirox Hybrids
por: Gascon, Jose Miguel, et al.
Publicado: (2019)

Comparison of the effects of deferasirox, deferoxamine, and combination of deferasirox and deferoxamine on an aplastic anemia mouse model complicated with iron overload
por: Wu, Dijiong, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_g64rskc354170dgj0nmg3nadvj